Search results
Showing 1 to 11 of 11 results for selinexor
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
In development Reference number: GID-TA11201 Expected publication date: 26 February 2026
Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]
Awaiting development Reference number: GID-TA11938 Expected publication date: TBC
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Awaiting development Reference number: GID-TA10694 Expected publication date: TBC
In development Reference number: GID-TA11203 Expected publication date: 08 April 2026
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Awaiting development Reference number: GID-TA11941 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections